Rallybio(RLYB) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Recent Business Highlights and Upcoming Milestones: RLYB116 Program • Rallybio is on track to initiate dosing in the RLYB116 confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study in the second quarter of 2025. Results from Cohort 1 (150 mg once weekly) and Cohort 2 (225 mg once weekly) are anticipated in the third and fourth quarter of 2025, respectively. Data from this study are expected to demonstrate complete and sustained complement inhibition with improved tolerability of RLY ...